NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

QUALCOMM Incorporated (NASDAQ: QCOM) Class Period: January 31, 2018 - March 12, 2018 Lead Plaintiff Deadline: August 7, 2018 Join the action: http://www.zlk.com/pslra-d/qualcomm-investigation?wire=3

Allegations: QUALCOMM Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) Qualcomm had secretly filed a unilateral notice with CFIUS in order to frustrate Broadcom's attempt to acquire the Company; and (2) investors suffered damages as a result of defendants' wrongful acts and omissions. On March 5, 2018, Broadcom announced that Qualcomm had filed a voluntary request for The Committee on Foreign Investment in the United States to initiate an investigation into Broadcom’s actions. Broadcom referred to this as a “blatant, desperate act by Qualcomm to entrench its incumbent board of directors and prevent its own stockholders from voting for Broadcom’s independent director nominees.”

To learn more about the QCOM class action contact jlevi@levikorsinsky.com.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 - July 9, 2018 Lead Plaintiff Deadline: September 17, 2018 Join the action: http://www.zlk.com/pslra-d/acadia?wire=3

Allegations: ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the ACAD class action contact jlevi@levikorsinsky.com.

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018 Lead Plaintiff Deadline: September 25, 2018 Join the action: http://www.zlk.com/pslra-d/tetraphase-pharmaceuticals-inc?wire=3

The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and (3) consequently, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the TTPH class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com